Agios Pharmaceuticals Inc (NASDAQ:AGIO) Director John Maraganore sold 13,555 shares of the stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $72.75, for a total value of $986,126.25. Following the completion of the sale, the director now owns 38,609 shares of the company’s stock, valued at $2,808,804.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Agios Pharmaceuticals stock opened at $73.44 on Friday. Agios Pharmaceuticals Inc has a 1 year low of $51.62 and a 1 year high of $99.82. The stock has a market capitalization of $4.30 billion, a price-to-earnings ratio of -10.88 and a beta of 1.77.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.62) by $0.43. The business had revenue of $40.40 million during the quarter, compared to the consensus estimate of $12.47 million. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. Agios Pharmaceuticals’s quarterly revenue was up 257.5% on a year-over-year basis. During the same period last year, the company earned ($1.78) earnings per share. sell-side analysts predict that Agios Pharmaceuticals Inc will post -6.01 EPS for the current fiscal year.

Several equities research analysts have issued reports on the company. BidaskClub downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th. Piper Jaffray Companies restated a “buy” rating on shares of Agios Pharmaceuticals in a report on Monday, June 4th. Cann restated a “hold” rating on shares of Agios Pharmaceuticals in a report on Friday, July 20th. SunTrust Banks restated a “buy” rating and issued a $123.00 price target on shares of Agios Pharmaceuticals in a report on Monday, July 23rd. Finally, Citigroup assumed coverage on Agios Pharmaceuticals in a report on Wednesday, May 23rd. They issued a “buy” rating and a $117.00 price target for the company. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $97.90.

Large investors have recently bought and sold shares of the stock. Woodford Investment Management Ltd bought a new position in shares of Agios Pharmaceuticals during the second quarter worth about $32,849,000. Barrett Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the second quarter worth about $253,000. State of Alaska Department of Revenue grew its holdings in shares of Agios Pharmaceuticals by 32.7% during the second quarter. State of Alaska Department of Revenue now owns 5,960 shares of the biopharmaceutical company’s stock worth $501,000 after buying an additional 1,470 shares in the last quarter. NewSquare Capital LLC bought a new position in shares of Agios Pharmaceuticals during the second quarter worth about $182,000. Finally, Principal Financial Group Inc. grew its holdings in shares of Agios Pharmaceuticals by 11.5% during the first quarter. Principal Financial Group Inc. now owns 14,895 shares of the biopharmaceutical company’s stock worth $1,218,000 after buying an additional 1,533 shares in the last quarter. Institutional investors and hedge funds own 93.64% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Further Reading: How do investors use RSI to grade stocks?

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.